NASDAQ:IFRX InflaRx (IFRX) Stock Price, News & Analysis $2.62 +0.16 (+6.28%) As of 12:53 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About InflaRx Stock (NASDAQ:IFRX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get InflaRx alerts:Sign Up Key Stats Today's Range$2.51▼$2.7050-Day Range$0.83▼$2.6552-Week Range$0.71▼$2.95Volume686,789 shsAverage Volume1.16 million shsMarket Capitalization$189.76 millionP/E RatioN/ADividend YieldN/APrice Target$7.00Consensus RatingModerate Buy Company Overview InflaRx N.V. is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies targeting the complement system, with an emphasis on the complement‐1a (C5a) pathway. The company’s lead product candidate, vilobelimab (IFX‐1), is a monoclonal antibody designed to selectively inhibit C5a, a potent pro‐inflammatory peptide implicated in a range of autoimmune and inflammatory diseases. InflaRx seeks to address high‐unmet medical needs by advancing treatments for conditions such as hidradenitis suppurativa, pyoderma gangrenosum and other rare and severe inflammatory disorders. Vilobelimab has been evaluated in multiple Phase II trials, demonstrating proof of concept in reducing key inflammatory markers and improving clinical outcomes. In addition to its lead program, InflaRx is developing complementary C5a receptor antagonists and novel anti‐inflammatory antibodies in earlier stages of development. The company’s research efforts leverage proprietary antibody engineering and target validation platforms to identify and optimize molecules with high specificity and favorable safety profiles. Founded in 2007, InflaRx is headquartered in Jena, Germany, with a subsidiary in Bernardsville, New Jersey. The company maintains a global footprint by collaborating with academic institutions, contract research organizations and key opinion leaders across Europe and North America. InflaRx completed its initial public offering on the Nasdaq Global Market in 2017, reflecting its commitment to advancing innovative therapies from bench to bedside. Under the leadership of Chief Executive Officer Michael Ernst, M.D., InflaRx is supported by a management team with extensive experience in immunology, drug development and commercial strategy. The company continues to expand its clinical development capabilities as it works toward regulatory milestones and potential partnerships to bring its anti‐C5a therapies to patients worldwide.AI Generated. May Contain Errors. Read More InflaRx Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks55th Percentile Overall ScoreIFRX MarketRank™: InflaRx scored higher than 55% of companies evaluated by MarketBeat, and ranked 439th out of 858 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingInflaRx has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on 1 strong buy rating, 4 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialInflaRx has a consensus price target of $7.00, representing about 162.7% upside from its current price of $2.67.Amount of Analyst CoverageInflaRx has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about InflaRx's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for InflaRx are expected to decrease in the coming year, from ($0.51) to ($0.54) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of InflaRx is -3.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of InflaRx is -3.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioInflaRx has a P/B Ratio of 4.44. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about InflaRx's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.29% of the float of InflaRx has been sold short.Short Interest Ratio / Days to CoverInflaRx has a short interest ratio ("days to cover") of 0.94, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in InflaRx has recently increased by 10.14%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldInflaRx does not currently pay a dividend.Dividend GrowthInflaRx does not have a long track record of dividend growth. News and Social Media1.3 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for InflaRx this week, compared to 3 articles on an average week.Search Interest12 people have searched for IFRX on MarketBeat in the last 30 days. This is an increase of 71% compared to the previous 30 days.MarketBeat Follows3 people have added InflaRx to their MarketBeat watchlist in the last 30 days. Company Ownership1.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, InflaRx insiders have not sold or bought any company stock.Percentage Held by Insiders16.30% of the stock of InflaRx is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions42.39% of the stock of InflaRx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about InflaRx's insider trading history. Receive IFRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for InflaRx and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IFRX Stock News HeadlinesInflaRx N.V. (NASDAQ:IFRX) Receives $7.00 Average PT from BrokeragesMay 19 at 4:53 AM | americanbankingnews.comRaymond James upgrades InflaRx NV (IFRX)May 14, 2026 | msn.comSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billion - you'd be buying at $1.75 trillion. But one small, publicly traded company sits directly in SpaceX's path, still priced like Wall Street hasn't noticed. It powers the infrastructure Musk's operation can't run without. Dylan Jovine is naming the ticker free - before the June S-1 closes the window.May 22 at 1:00 AM | Behind the Markets (Ad)InflaRx NV (IFRX) price target decreased by 16.67% to 7.29May 14, 2026 | msn.comInflaRx (NASDAQ:IFRX) Upgraded to Strong-Buy at Raymond James FinancialMay 14, 2026 | americanbankingnews.comCantor Fitzgerald Issues Positive Forecast for InflaRx (NASDAQ:IFRX) Stock PriceMay 12, 2026 | americanbankingnews.comInflaRx Highlights Favorable Safety-Signal Data for Izicopan in New Preclinical StudyMay 9, 2026 | theglobeandmail.comInflaRx N.V. (IFRX) Discusses Strategic Focus on Izicopan for ANCA-Associated Vasculitis and Renal Diseases TranscriptMay 8, 2026 | seekingalpha.comSee More Headlines IFRX Stock Analysis - Frequently Asked Questions How have IFRX shares performed this year? InflaRx's stock was trading at $1.01 at the beginning of 2026. Since then, IFRX stock has increased by 163.9% and is now trading at $2.6650. How were InflaRx's earnings last quarter? InflaRx N.V. (NASDAQ:IFRX) posted its earnings results on Thursday, May, 7th. The company reported ($0.09) earnings per share for the quarter, beating the consensus estimate of ($0.17) by $0.08. When did InflaRx IPO? InflaRx (IFRX) raised $100 million in an initial public offering (IPO) on Wednesday, November 8th 2017. The company issued 6,667,000 shares at $14.00-$16.00 per share. J.P. Morgan, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO. Who are InflaRx's major shareholders? Top institutional shareholders of InflaRx include Bank of America Corp DE (2.73%) and ADAR1 Capital Management LLC (0.22%). How do I buy shares of InflaRx? Shares of IFRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of InflaRx own? Based on aggregate information from My MarketBeat watchlists, some other companies that InflaRx investors own include Xeris Biopharma (XERS), Bristol Myers Squibb (BMY), Enterprise Products Partners (EPD), Exelixis (EXEL), Tesla (TSLA) and Alibaba Group (BABA). Company Calendar Last Earnings5/07/2026Today5/22/2026Next Earnings (Estimated)8/06/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 IFRX's financial health is in the Green zone, according to TradeSmith. IFRX has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:IFRX CIK1708688 Webwww.inflarx.de Phone493641508180Fax49-36-4150-8181Employees60Year Founded2006Price Target and Rating Average Price Target for InflaRx$7.00 High Price Target$14.00 Low Price Target$2.00 Potential Upside/Downside+166.7%Consensus RatingModerate Buy Rating Score (0-4)2.71 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)($0.71) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$51.63 million Net MarginsN/A Pretax Margin-149,706.05% Return on Equity-88.30% Return on Assets-65.77% Debt Debt-to-Equity RatioN/A Current Ratio4.16 Quick Ratio4.16 Sales & Book Value Annual Sales$30 thousand Price / Sales6,325.38 Cash FlowN/A Price / Cash FlowN/A Book Value$0.60 per share Price / Book4.38Miscellaneous Outstanding Shares72,290,000Free Float60,509,000Market Cap$189.76 million OptionableOptionable Beta2.42 Social Links (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:IFRX) was last updated on 5/22/2026 by MarketBeat.com Staff. From Our PartnersHow to Profit from Elon’s AI lab before it goes publicElon Musk's AI lab has partnered with the Department of Defense, Oracle, and Palantir - and he just filed conf...InvestorPlace | SponsoredMaybe the Greatest Strategy of the DecadeNate Bear, Lead Technical Tactician at Monument Traders Alliance, is going public with his highest-conviction ...Monument Traders Alliance | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredThe SpaceX supplier that shipped 5 billion chips to StarlinkWhen Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, suppli...Weiss Ratings | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredOne filing just changed the SpaceX IPO foreverSpaceX just filed its S-1. The IPO is confirmed for June 12 - $75 billion, ticker SPCX, potentially the larges...Behind the Markets | SponsoredSpaceX controls two-thirds of all satellites - and it is about to go publicSpaceX is targeting an IPO on June 11th, with trading set to begin June 12th and the roadshow kicking off June...NXT Wave Research | SponsoredTo Avoid 67 Million Blackouts, Trump Signs Emergency Backing of New Energy TechPresident Trump has used emergency executive powers to back a new energy technology described as 326 times mor...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding InflaRx N.V. Please log in to your account or sign up in order to add this asset to your watchlist. Share InflaRx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
